Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0233 in healthy volunteers
NCT06381466Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD0233 in dilated cardiomyopathy (DCM) (11 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events and Serious Adverse Events. Started Apr 2024; status: terminated.
02
Drugs
AZD0233
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT06381466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381466.